Bright Minds Biosciences Inc (DRUG) Stock Price & News

Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia

About Bright Minds Biosciences Inc

CEO-

Employees26

Founded2017

Headquarters-

Sector-

Websitebrightmindsbio.com

All values in CAD	Sep. 2025	Des. 2025	Mrt. 2026	Jun. 2026
Revenue	-	-	-	-
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	4,78 m	5,66 m	13,05 m	9,25 m
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	749,11 k	1,08 m	2,23 m	2,15 m
Operating expense	5,79 m	6,74 m	15,28 m	11,41 m
Total operating expenses	5,79 m	6,74 m	15,28 m	11,41 m
Operating income	-5,79 m	-6,74 m	-15,28 m	-11,41 m
Other non operating income	-123,93 k	-154,22 k	-42,48 k	-27,84 k
EBT including unusual items	-4,09 m	-7,57 m	-10,46 m	-2,40 m
EBT excluding unusual items	-4,09 m	-7,57 m	-10,46 m	-2,40 m
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	257,87 k	-	-	-
Net income	-4,09 m	-7,57 m	-10,46 m	-2,40 m
Net profit margin	-	-	-	-
Earnings per share	-0,58	-0,97	-1,09	-0,24
Interest and investment income	529,54 k	818,26 k	2,69 m	2,79 m
Interest expense	-7,30 k	-6,58 k	-	-
Net interest expenses	522,24 k	811,69 k	2,69 m	2,79 m
Depreciation and amortization charges	-	-	-	-
EBITDA	-	-	-	-
Gain or loss from assets sale	-	-	-	-

Ask anything